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OBJECTIVES The aims of the study were to determine the incidence of relocation of the minimal luminal
diameter (MLD) after beta-radiation therapy following balloon angioplasty (BA) and to
describe a new methodological approach to define the effect of brachytherapy on treated
coronary stenoses.
BACKGROUND Luminal diameter of coronary lesions may increase over time following angioplasty and
irradiatation. As a result, the MLD at follow-up may be relocated from its location
preintervention, which may induce misleading results when a restricted definition of the
target segment by quantitative coronary angiography (QCA) is performed.
METHODS Patients treated with BA followed by intracoronary brachytherapy according to the Dose-
Finding Study constituted the study population. A historical cohort of patients treated with
BA was used as control group. To be included in the analysis, an accurate angiographic
documentation of all instrumentations during the procedure was mandatory. In the irradiated
patients, four regions were defined by QCA: vessel segment (VS), target segment (TS),
injured segment (INS), and irradiated segment (IRS).
RESULTS Sixty-five patients from the Dose-Finding Study and 179 control patients were included. At
follow-up, MLD was relocated more often in the radiation group (78.5% vs. 26.3%; p ,
0.0001). The rate of .50% diameter stenosis differed among the four predefined regions:
3.1% in the TS; 7.7% in the INS; 9.2% in the IRS and 13.8% in the VS.
CONCLUSIONS Relocation of the MLD is commonly demonstrated after BA and brachytherapy, and it
should be taken into account during the analysis of the results of radiation clinical trials. (J
Am Coll Cardiol 2000;36:1536–41) © 2000 by the American College of Cardiology
During the past 10 years the efficacy of percutaneous
interventions in preventing restenosis has been assessed by
the use of quantitative coronary angiography (QCA) (1–4).
This technique of analysis has become the gold standard for
the assessment of coronary angiograms in the context of
scientific research due to its superior accuracy and objectivity
as compared to visual and hand-held caliper measurements;
in addition, it possesses a better inter- and intra-observer
variability (5,6). Consequently, the percent diameter steno-
sis has become the usual output of this analysis, and the
value of 50% has gained widespread acceptance to define the
presence of restenosis in the treated coronary segment (7).
Intravascular ultrasound (IVUS) studies demonstrated that
restenosis after balloon angioplasty (BA) is mainly due to
neointimal hyperplasia and vessel shrinkage at the site of the
injury (8–10).
Pioneers in intracoronary radiation therapy have demon-
strated that in a majority of patients the luminal diameter at
the site of the treated lesion may increase during the
follow-up, rather than decrease (11). Three-dimensional
IVUS analysis has shown that this phenomenon is induced
by positive remodeling of the vessel wall at the site of the
irradiated segment (IRS) (12). As a result, the minimal
luminal diameter (MLD) of coronary segments treated with
brachytherapy following percutaneous interventions may be
relocated at follow-up from its location pre-intervention. A
restricted definition of the target segment by QCA could
induce misleading results and make any comparison to
previous nonradiation studies unfair. This study was in-
tended to 1) determine the incidence of the relocation of the
MLD after beta-radiation therapy following successful BA
and 2) to describe a new methodological approach to
analyze and report accurately the effect of brachytherapy on
the treated coronary artery.
METHODS
Patient selection. Patients eligible for the study were those
successfully treated with BA followed by intracoronary
radiation according to the Boston Scientific/Schneider
Dose-Finding Study (13). The purpose of this trial was to
determine the effect of various doses of beta-irradiation on
coronary artery restenosis after BA with or without stent
implantation in patients with single de novo lesions of
native coronary arteries. The isotope selected was the pure
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beta-emitting 90Y, and patients were randomized to receive
doses of 9, 12, 15 or 18 gray (Gy) at 1 mm tissue depth. The
delivery of radiation was carried out by the use of the
Schneider-Sauerwein Intravascular Radiation System (14).
In brief, this system comprises 1) a flexible coil made of
titanium-coated pure yttrium affixed at the end of a thrust
wire between proximal and distal tungsten markers; 2) a
centering catheter, which is a segmented balloon consisting
of four interconnected compartments and which allows the
source lumen to be centered relative to the arterial lumen;
and 3) a computerized afterloader that allows automated
advancement and positioning of either the dummy or the
active source (14).
QCA analysis and definitions. The QCA analysis was
performed off-line by an independent core laboratory (Car-
dialysis, Rotterdam, The Netherlands). All angiograms
were evaluated after intracoronary administration of ni-
trates. Analysis was performed by means of the CAAS II
analysis system (Pie Medical BV, Maastricht, The Nether-
lands). Calibration of the system was based on dimensions
of the catheters unfilled with contrast medium. This
method of analysis has been previously validated (4,15,16).
The area of interest was selected after reviewing all cinefilms
performed during the index procedure. Any angiographic
sequence showing the lesion preintervention, positions of
angioplasty balloon and radiation source can be displayed
simultaneously on the screen using the Rubo DICOM
Viewer (Rubo Medical Imaging, Uithoorn, The Nether-
lands). The electrocardiographic (ECG) tracing is also
displayed in any angiographic sequence. By selecting frames
in the same part of the cardiac cycle, we were able to define
the location of the radiation source and angioplasty balloon
relative to the original lesion. The analyst defined a coronary
segment bordered by angiographically visible side branches
that encompassed the original lesion, angioplasty balloon
and radiation source. This segment was defined as the
“vessel segment” (VS) (Fig. 1). The MLD was determined
in the VS pre-intervention by edge detection and was
averaged from the two orthogonal projections. Reference
diameter was automatically calculated for the VS by the
interpolated method (4). The percent diameter stenosis was
calculated from the MLD and the reference diameter (7).
At the time of the procedure, all angioplasty balloons,
when deflated, were filmed in place with contrast injection
in the same projections as were the VS. After successful BA,
intracoronary brachytherapy was performed. Both the loca-
tion of the centering balloon and the active wire in place
Abbreviations and Acronyms
BA 5 balloon angioplasty
Gy 5 gray
INS 5 injured segment
IRS 5 irradiated segment
IVUS 5 intravascular ultrasound
MLD 5 minimal luminal diameter
QCA 5 quantitative coronary angiography
TS 5 target segment
VS 5 vessel segment
Figure 1. (A) Target segment (TS) is between proximal and distal margin of the target lesion, automatically defined by the quantitative coronary
angiography system. Vessel segment (VS) is bordered by visible side branches, which encompass the target segment (TS) and the position of the angioplasty
balloon and radiation source. (A*) Original lesion in the middle part of the right coronary artery before intervention. (B) Injured segment (INS) is defined
as the segment encompassed by the most proximal and most distal marker of the angioplasty balloon. (B*) Arrows indicate the markers of the deflated
angioplasty balloon filmed in place with a contrast injection. (C) The segment encompassed by the inner part of the two tungsten markers of the radiation
delivery system defined as the irradiated segments (IRS). (C*) Arrows indicate the inner parts of the radiation source tungsten markers filmed with a contrast
injection.
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were filmed in the same projections as performed previously.
The proximal side branch within the VS was used as an
index anatomical landmark. The CAAS software computed
distances from this proximal sidebranch to 1) the inner part
of the proximal tungsten marker, 2) the proximal marker of
the angioplasty balloon, 3) the proximal margin of the
obstruction segment, 4) the distal margin of the obstruction
segment, 5) the distal marker of the angioplasty balloon, and
6) the inner part of the distal tungsten marker. The “target
segment” (TS) was encompassed by the proximal and distal
margin of the obstructed segment. The segment encom-
passed by the most proximal and most distal marker of the
angioplasty balloon defined the “injured segment” (INS).
The segment encompassed by the inner part of the two
tungsten markers defined the IRS (Fig. 1). All regions of
interest were superimposed on the pre-, post-procedural and
follow-up angiograms. “Geographical miss” was defined for
those cases in which the entire length of the INS was not
fully covered by the IRS (17).
Using the software of the CAAS system, the analyst is
able to perform a subsegmental analysis within the VS. The
segment is automatically divided into subsegments of equi-
distant length (on average, 5.0 6 0.3 mm). The subsegment
containing the MLD was taken as the index segment, and
this enabled relocation of the MLD to be defined (Fig. 2).
“Relocation pre-post” was defined as those cases in which
the MLD of the VS post-treatment was located in a
different subsegment in the two orthogonal projections from
that of the index procedure. “Relocation post-fup” was
defined as those cases in which the MLD of the VS at
follow-up was located in a different subsegment in the two
orthogonal projections from that of the post-procedure.
“Relocation pre-fup” was defined as those cases in which the
MLD of the VS at follow-up was located in a different
segment in the two orthogonal projections from that of the
index procedure (Fig. 2).
Additionally, the analyst computed the MLD in every
region of interest and calculated the acute gain, the late loss
and the frequency of .50% diameter stenosis on a regional
basis. “Acute gain” was defined as MLD posttreatment
minus MLD preintervention. “Late loss” was defined as
MLD posttreatment minus MLD at follow-up. “Resteno-
sis” was defined as diameter stenosis .50% at follow-up.
Control group. A historical cohort of consecutive patients
treated with BA from the BENESTENT II trial (18) and
presenting with matched views and correct angiographic
documentation was used as the control group. The VS, TS,
and relocation of the MLD were defined in this cohort as
described above.
Statistical analysis. Data are presented as mean 6 SD or
proportions. To compare qualitative variables, the chi-
square test was carried out. To compare quantitative vari-
ables, the Student t test was performed. All tests were
two-tailed, and a value of p , 0.05 was considered statis-
tically significant.
RESULTS
Baseline characteristics. One hundred and eighty-one pa-
tients were included in the dose-finding study. Of these, 51
patients received a stent. The remaining 130 patients treated
with BA alone followed by beta-radiation were eligible for
the study. By comparing the technician worksheet with the
angiograms recorded, the analyst was able to identify those
patients for whom all balloon inflations and source posi-
tioning were filmed and all target views matched. Using this
Figure 2. (A) Subsegmental analysis before procedure. Vessel segment (VS) was automatically divided into 5-mm subsegments by the CAAS II system.
The original lesion is located at segment No. 5 preprocedure as the arrow indicates. (A*) Computer defined analysis preprocedure. (B) Subsegmental analysis
at postprocedure. Minimum lumen diameter is located at segment No. 6 (arrow). (B*) Computer-defined analysis postprocedure. (C) Subsegmental analysis
at follow-up. Minimum lumen diameter is located at segment No. 7 (arrow). (C*) Computer-defined analysis at follow-up.
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systematic approach, 65 patients who did not accomplish
these technical requirements for performing an accurate
QCA were excluded from the study. Thus, the study
population comprised the 65 patients presenting with com-
plete and correct angiographic documentation. All patients,
regardless of the dose prescribed (9, 12, 15, or 18 Gy at
1 mm tissue depth), were pooled together.
Of 410 patients enrolled in the balloon arm of the
BENESTENT II trial, 179 presenting with all the above-
mentioned technical requirements constituted the control
group. Baseline characteristics of both the study population
and control group are described in Table 1. No differences
were observed between the two groups.
Incidence and location of the relocation of the MLD.
Relocation pre-post of the MLD was defined in 36 patients
(55.4%) in the dose-finding cohort and in 62 patients
(34.6%) in the control group (p 5 0.005); relocation
post-fup was defined in 37 patients (56.9%) in the dose-
finding cohort and in 59 patients (33.0%) in the control
group (p 5 0.001); and relocation pre-fup was defined in 51
patients (78.5%) in the dose-finding cohort and in 47
patients (26.3%) in the control group (p , 0.0001). Geo-
graphical miss was identified in two patients (3%). At
follow-up, 45 patients (69.2%) presented with an increase in
the value of MLD at TS, whereas 20 patients (30.8%)
demonstrated either a decrease (18 patients) or no change (2
patients) in the value of MLD at TS. The location of the
MLD in cases of relocation is presented in Table 2. This
new MLD was most commonly located within the IRS and
INS, followed by those regions within the VS but outside
the IRS and the INS. Typically, when the new MLD was
located outside the INS and IRS, distal subsegments were
most often involved rather than the proximal ones (88% vs.
12%, respectively).
Methodological implications of the relocation of the
MLD. The QCA data derived from the analysis of the
predefined regions are shown in Table 3.
DISCUSSION
Incidence and causes of relocation of the MLD. This
study demonstrates that the relocation of the MLD is a
common phenomenon in coronary segments treated with
BA followed by intracoronary beta-radiation therapy. Al-
though relocation of the MLD at follow-up was signifi-
cantly more frequent in the irradiated group, control pa-
tients treated with “plain old balloon” angioplasty also
demonstrated a notable incidence of relocation. This phe-
nomenon was noted after radiation was witnessed in previ-
ous studies showing that the restenosis process affected the
entire vessel segment, which was dilated, and not just the
obstructed segment (19,20). To overcome this problem, the
Total Occlusion Study of Canada (TOSCA) group devised
the concept of “target lesion work length,” defined as the
length of contiguous target segment exposed to balloon
inflation (21). In addition, the relocation of the MLD may
explain the mismatch between good angiographic results of
Table 1. Baseline Characteristics
Dose-
Finding
Group
(n 5 65)
Control
Group
(n 5 179)
Age (yrs) 64 6 9 62 6 10
Gender (male) 46 (70.7%) 137 (76.5%)
Treated artery
Left anterior descending 28 (43.1%) 80 (44.7%)
Left circumflex 7 (10.8%) 22 (12.3%)
Right coronary 30 (46.1%) 77 (43%)
Coronary risk factors
Systemic hypertension 35 (53.8%) 89 (49.7%)
Diabetes mellitus 12 (18.5%) 27 (15%)
Smoking 33 (66.1%) 123 (68.7%)
Hypercholesterolemia 38 (58.5%) 98 (54.7%)
Family history 23 (35.4%) 60 (33.5%)
Dose
9 Gy 18 (27.7%) —
12 Gy 11 (16.9%) —
15 Gy 20 (30.8%) —
18 Gy 16 (24.6%) —
All p 5 NS. Gy 5 gray.
Table 2. Location of the Relocated MLD
Relocation
Pre-post
(n 5 36)
Relocation
Post-fup
(n 5 37)
Relocation
Pre-fup
(n 5 51)
Within INS–IRS 19 (52.9%) 23 (62.2%) 24 (47%)
Outside INS–IRS 9 (25%) 10 (27%) 18 (35.3%)
Within IRS–outside INS 6 (16.6%) 4 (10.8%) 8 (15.7%)
Within INS–outside IRS
(geographical miss)
2 (5.5%) 0 (0%) 1 (2%)
INS 5 injured segment; IRS 5 irradiated segment.
Table 3. QCA Data From the Four Predefined Segments
TS INS IRS VS
MLD pre (mm) 1.06 6 0.2 1.06 6 0.2 1.06 6 0.2 1.06 6 0.2
MLD post (mm) 2.17 6 0.5 1.99 6 0.4 2.00 6 0.4 1.91 6 0.4
MLD fup (mm) 2.36 6 0.5 1.97 6 0.5 1.97 6 0.5 1.84 6 0.5
%DS fup 20.3 6 11 33.2 6 11 33.4 6 11 37.9 6 10
Acute gain (mm) 1.12 6 0.4 0.93 6 0.4 0.94 6 0.4 0.85 6 0.4
Late loss (mm) 20.18 6 0.4 0.01 6 0.4 0.03 6 0.4 0.07 6 0.3
Restenosis rate, n (%) 2 (3.1) 5 (7.7) 6 (9.2) 9 (13.8)
Segment length (mm) 5.0 6 0.3 18.7 6 4.2 22.9 6 3.5 36.9 6 8.4
DS 5 diameter stenosis; fup 5 follow-up; INS 5 injured segment; IRS 5 irradiated segment; MLD 5 minimal luminal diameter; pre 5 pre-intervention; post 5
post-intervention; TS 5 target segment; VS 5 vessel segment.
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previous radiation trials and the poor clinical outcome (i.e.,
high target vessel revascularization rates) observed in these
studies (22).
Further, because changes in the reference diameter may
occur during the follow-up period, the use of the percent
diameter stenosis measurements is questionable as an accu-
rate estimate of lesion severity (19,20). In this regard, two
thirds of our study population demonstrated an increase in
the value of the preintervention MLD. In the radiation
group, increase of vessel dimensions at the site of the index
MLD may play an important role in the relocation of the
MLD.
Previous three-dimensional IVUS observations demon-
strated that the vessel wall enlarges after catheter-based
radiation therapy either following conventional BA or stent
implantation (12,23). This vessel enlargement was able to
accommodate the mean increase in plaque volume, resulting
in a net increase in the irradiated luminal volume at
follow-up.
In our study, the MLD was mainly relocated within the
IRS and the INS and outside the INS and the IRS (typically
at distal segments). In such regions, the presence of pre-
existing plaques that became angiographically apparent or
that progressed after the treatment and tapering of the vessel
may have accounted for the relocation of the MLD. In
addition to these causes of relocation, we cannot exclude the
influence of the natural atherosclerotic process on this
phenomenon in the context of patients with coronary risk
factors by inducing development of new coronary lesions in
any of the predefined regions of interest.
Methodological consequences of relocation. When the
analysis was restricted to the TS, this lumen gain at
follow-up resulted in a negative mean late loss and a very
low restenosis rate (3.1%). The TS represents a region that
was injured by the balloon and theoretically presented with
the peak stress and vessel stretch after BA. Further, this
segment was fully covered by the radiation source in all
cases. Thus, the results of the analysis of the TS may
demonstrate the effect of brachytherapy under optimal
conditions. On the other side of the spectrum, when the
analysis included the entire VS, both the late loss and the
restenosis rate were significantly higher (Table 3). This
latter analysis was performed in most of the historical trials
aimed to determine effectiveness of new therapeutic agents
on the restenosis process after BA (24–27). This traditional
approach is driven by the concern that hemodynamic effects
(i.e., flow-limiting lesion), symptoms, and outcomes are
likely related to the location of the new MLD, irrespective
of precise anatomic concordance with its location pre-
intervention. The meticulous analyses proposed are likely to
yield new insights on the pathophysiology of this new
therapy, and we believe that these are highly recommended
during feasibility in vivo and in vitro studies. In clinical
radiation trials, the traditional VS approach should be the
common angiographic end point, and further analyses of the
above-defined regions of interest may complement the
results of the study. In this regard, the efficacy of the therapy
itself would be determined by the results at the TS, whereas
the effectiveness of the radiation therapy would be defined
for the entire VS, which includes both the desired (i.e.,
lumen enlargement) and the side effects (i.e., edge resteno-
sis).
Study limitations. The definition of relocation of the
MLD depends decisively on the accurate documentation of
all steps followed during the procedure. This was accom-
plished in only 50% of the cases treated with BA in the dose
finding study and in 44% of the historical control group.
The QCA data presented in this study represent only the
results of the pooled cohort of patients enrolled in the dose
finding study, and not the entire population.
Conclusions. Relocation of the MLD is a common phe-
nomenon after successful BA followed by intracoronary
beta-radiation. This feature may induce controversial results
related to the methodology used in the QCA analysis and
should be considered when reporting the results of subse-
quent radiation studies. The new methodological approach
proposed may be useful to determine both the potentialities
and the limitations of this new technique.
APPENDIX
The participating centers and investigators of the Dose-
Finding Study Group are listed along with the number of
included patients in parentheses.
University Hospital, Geneva, Switzerland (57): Vitali
Verin, MD, Touri Popowski, MD, Patrice Delafontaine,
MD, John Kurtz, MD, Igor Papirov, PhD, Sergey Airiian,
MD, Philippe Debruyne, MD, Jose Ramos de Olival, MD.
Cardiovascular Center, Onze-Lieve-Vrouw Ziekenhuis,
Aalst, Belgium (54): William Wijns, MD (Principal Inves-
tigator), Bernard de Bruyne, MD, Guy Heyndrickx, MD,
Luc Verbeke, MD, Marleen Piessens, PhD, Jo De Jans,
MSc.
University Hospital, Essen, Germany (26): Dietrich Baum-
gart, MD, Wolfgang Sauerwein, MD, Raimund Erbel,
MD, Clemens von Birgelen, MD, Michael Haude, MD.
University Hospital, Kiel, Germany (22): Markus Lins,
MD, Simon Ruediger, MD, Gyorgy Kovacs, MD, Thomas
Martin, MD, Herrmann Gunhild, MD, Wilhelm Roland,
MD, Peter Kohl, MD.
Kings College Hospital, London, United Kingdom (22):
Thomas Martin, MD, Francis Calman, MD, Niel Lewis,
PhD.
Data monitoring. Thomas Thaler, MD (Boston, Scientif-
ic).
Angiographic core-laboratory and data analysis. Yvonne
Teunissen, PhD (Clinical Trial Manager), Astrid Spierings,
MSc, Connie Van der Wiel, MSc, Gitte Kloek, MSc,
Clemens Disco, PhD.
Critical Events Committee. Jaap Dekkers MD, Patrick
Serruys, MD, PhD.
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